On the value of intensive remission‑induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

Rákkutatás · Acute myeloid leukemia

Intensive remission‑induction chemotherapy improves overall survival compared with a wait‑and‑see supportive care strategy in patients aged 65 years or older with acute myeloid leukemia.

A prospective randomized phase III study compared immediate intensive‑induction chemotherapy (daunorubicin, vincristine, cytarabine) followed by consolidation in complete responders to a wait‑and‑see/supportive care strategy in patients aged >65 years with acute myeloid leukemia. Thirty‑one patients received intensive induction; 29 received supportive care. The intensive arm had a median overall survival of 21 weeks versus 11 weeks for the supportive arm (P = .015), and a 2.5‑year projected survival of 13% versus 0%. Complete remission was achieved in 58% of the intensive group and none in the supportive group. The study suggests intensive induction improves survival in elderly AML patients, albeit with modest remission rates and limited long‑term benefit.

Elderly patients with AML have limited treatment options; demonstrating that intensive induction can extend survival informs clinical decision‑making and supports balanced discussions of benefit versus toxicity in this vulnerable population.

Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Eredeti forrás

Kapcsolódó jelek